The Synedica Retatrutide Triple Agonist 40mg is a research product listed within the wider peptide and biotechnology catalogue. It contains Retatrutide, an investigational compound associated with research into three receptor pathways: GIP, GLP-1 and glucagon.
This page provides product information, research context and frequently asked questions for visitors researching the formulation.
The current catalogue lists the product as a 40mg total formulation with a displayed price of £110. Product availability and pricing can change, so visitors should check the current product listing before making any purchasing decision.
Research-use notice: This information is provided for scientific, educational and laboratory research purposes. The product is not presented as a medicine, treatment, dietary supplement or recommendation for human or veterinary use.
Product Overview
Product name: Synedica Retatrutide Triple Agonist Injection Pen Kit
Total stated quantity: 40mg
Research compound: Retatrutide
Research category: Peptide research
Product focus: Triple-receptor research
Current listed price: £110
Primary product keyword: Synedica Retatrutide Triple Agonist
The catalogue places this formulation alongside other peptide research products, including Retatrutide, CagriReta, CagriSema, Tirzepatide and Semaglutide formulations.
What Is the Retatrutide Triple Agonist?
Retatrutide is an investigational peptide that has attracted scientific interest because of its activity across three receptor systems.
These pathways are:
- GIP
- GLP-1
- Glucagon
For research purposes, the combination is particularly relevant when investigating interactions between multiple receptor pathways and their associated biological signalling.
The term triple agonist describes this three-pathway activity.
It does not mean that the product is an approved medicine, nor should the term be interpreted as a therapeutic claim.
40mg Research Formulation
The product listing identifies the formulation as containing 40mg total.
When evaluating a research material, researchers should distinguish between the stated quantity of a formulation and assumptions about how a compound may be used.
Product information should always be checked against the specific listing and any documentation supplied with the relevant batch.
Important product details to review include:
- Stated compound
- Total quantity
- Product format
- Batch information
- Available analytical documentation
- Storage information
- Research-use restrictions
- Current regulatory information
This approach helps keep product evaluation focused on verifiable information rather than unsupported claims.
Retatrutide Research
Retatrutide is being investigated in the context of metabolic and receptor biology.
Its interaction with GIP, GLP-1 and glucagon pathways makes it relevant to research involving interconnected signalling systems.
Research into these pathways can examine areas such as:
- receptor signalling
- molecular interactions
- metabolic biology
- peptide structure
- biological response pathways
- pharmacological research
- experimental models
The scientific literature should remain the primary source for conclusions about experimental findings.
A product listing should provide factual product information rather than replace peer-reviewed research.
Why Researchers Search for Retatrutide
Interest in Retatrutide has created several related search terms across peptide research.
Common product and research searches can include:
- Retatrutide research
- Retatrutide 40mg
- Retatrutide triple agonist
- triple agonist peptide
- Retatrutide research material
- Retatrutide peptide research
- GIP GLP-1 glucagon research
- Retatrutide product information
The product page is designed to capture the informational relationship between these topics without making medical or treatment claims.
Product Information at a Glance
| Specification | Information |
|---|---|
| Product | Retatrutide Triple Agonist Injection Pen Kit |
| Stated total | 40mg |
| Compound | Retatrutide |
| Research category | Peptide research |
| Receptor research | GIP, GLP-1 and glucagon |
| Listed price | £110 |
| Intended context | Laboratory research |
The displayed product information is based on the current catalogue listing and should be rechecked when the page is updated.
What Makes This Product Different?
The main distinguishing feature is the compound’s association with three receptor pathways.
Many peptide research discussions focus on individual receptor systems. Retatrutide is studied in a different context because its molecular activity involves GIP, GLP-1 and glucagon.
That makes it relevant to researchers examining multi-pathway signalling.
However, a multi-receptor mechanism should not automatically be interpreted as evidence of a particular health outcome.
The appropriate research question depends on the experimental model, methodology and scientific literature being considered.
Research Product Documentation
Good research practice depends on accurate documentation.
Before evaluating any peptide research material, researchers should look for information relevant to the individual product and batch.
Depending on what is available, documentation may include:
- Product specification
- Batch identification
- Quantity
- Analytical information
- Laboratory testing
- Storage information
- Research-use statement
Where documentation is available, it should be considered alongside independent scientific evidence.
Researchers should avoid assuming that products with similar names necessarily have identical specifications.
Retatrutide and Modern Peptide Research
Peptide science has become an important area of modern biotechnology research.
Peptides can be studied for their interactions with receptors, proteins and signalling systems.
Retatrutide is one example of an investigational peptide being studied in relation to multiple receptor pathways.
The broader field includes research into receptor agonists, peptide structure, molecular signalling and experimental pharmacology.
This makes Retatrutide relevant to a wider scientific conversation about multi-pathway peptide research.
Frequently Asked Questions
What is Synedica Retatrutide Triple Agonist?
It is a 40mg Retatrutide research product listed within the current product catalogue.
What does triple agonist mean?
Triple agonist refers to Retatrutide’s activity across GIP, GLP-1 and glucagon receptor pathways.
How much Retatrutide is listed in the product?
The current product listing states a total quantity of 40mg.
What is the current listed price?
The current catalogue lists the product at £110. Prices can change, so the live product listing should be checked for the latest information.
Is Retatrutide an approved medicine in the UK?
The website itself states that Retatrutide is not authorised as a medicine in the UK. Visitors should consult current official UK regulatory information for the latest regulatory position.
Is this product intended for human use?
No. The website describes its research materials as intended for scientific, educational and laboratory research and not for human or veterinary use.
What receptor pathways are associated with Retatrutide research?
Retatrutide research involves GIP, GLP-1 and glucagon receptor pathways.
Where can I find other peptide research products?
The wider catalogue contains additional products covering several peptide and biotechnology research categories.
Research-Use Notice
This page provides general scientific and product information.
The material discussed is presented for laboratory research and educational purposes only.
Nothing on this page should be interpreted as medical advice, a diagnosis, treatment recommendation or instruction for human or veterinary use.
Retatrutide is an investigational compound. Regulatory status should be checked through current official sources.
Explore Related Research
Visitors researching this formulation may also find it useful to explore related product categories and individual research pages.
Relevant topics include:
- Retatrutide research
- CagriReta research
- CagriSema research
- Tirzepatide research
- Semaglutide research
- peptide biotechnology
- receptor signalling
- GIP research
- GLP-1 research
- glucagon research
Use contextual internal links to connect this page with the relevant product and category pages. This creates a logical topical structure rather than placing unrelated links throughout the copy.
Conclusion
The Retatrutide Triple Agonist 40mg is a research-focused formulation associated with investigation into GIP, GLP-1 and glucagon receptor pathways.
Its 40mg stated quantity, product format and research classification should be evaluated using the current product listing and any available supporting documentation.
For search visitors, this page provides a central source of product information while keeping the distinction between laboratory research materials and approved medicines clear.
